Expression profile of a γ-deletion variant of the human telomerase reverse transcriptase gene

Neoplasia

Volumn 5, Issue 3, 2003, Pages 193-197

  Hisatomi, Hisashi ^a   Ohyashiki, Kazuma ^b   Ohyashiki, Junko H ^b   Nagao, Kumi ^a   Kanamaru, Taichi ^c   Hirata, Hiroyuki ^a   Hibi, Nozomu ^a   Tsukada, Yutaka ^a  

^a SRL INC   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c KOBE ROSAI HOSPITAL   (Japan)

Author keywords

Alternative splicing; HTERT; Telomerase; Telomere; deleton ASV

Indexed keywords

HOLOENZYME; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

ALPHA CHAIN; ARTICLE; BETA CHAIN; CANCER CELL CULTURE; CHROMOSOME; ENZYME ACTIVITY; EXON; GENE DELETION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING;

EID: 0038239507     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80051-9     Document Type: Article

References (35)

1. Hanke J, Brett D, Zastrow I, Aydin A, Delbruck S, Lehmann G, Luft F, Reich J, and Bork P (1999). Alternative splicing of human genes more the rule than the exception. Trends Genet 15, 389-90.
2. Mironov AA, Fickett JW, and Gelfland MS (1999). Frequent alternative splicing of human genes. Genome Res 9, 1288-93.
3. van Der Houven Van Oordt W, Newton K, Screaton GR, and Caceres JF (2000). Role of SR protein modular domains in alternative splicing specificity in vivo. Nucleic Acids Res 28, 4822-31.
4. Pilch B, Allemand E, Facompre M, Bailly C, Riou JF, Soret J, and Tazi J (2001). Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res 61, 6876-84.
5. Stallings-Mann ML, Ludwiczak RL, Klinger KW, and Rottman F (1996). Alternative splicing of exon 3 of the human growth hormone receptor is the result of an unusual genetic polymorphism. Proc Natl Acad Sci USA 93, 12394-99.
6. Liu W, Qian C, and Francke U (1997). Silent mutation induces exon skipping of fibrillin-1 gene in Marfan syndrome. Nat Genet 16, 328-29.
7. Siffert W, Posskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, and Horsthemke B (1998). Association of human G-protein beta3 subunit variant hypertension. Nat Genet 18, 45-48.
8. Hisatomi H, Kohno N, Wakita K, Nagao K, Hirata H, Hikiji K, and Harada S (2003). A novel alternatively spliced variant with a deletion of 52 bp in exon 6 of the progesterone receptor gene is frequently observed in breast cancer. Int J Cancer (in press).
9. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Linger J, and Harley CB (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-59.
10. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, and Weinberg RA (1997). hEST2, putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-95.
11. Harrington L, Zhou W, McPhail T, Oulton R, Yeung DS, Mar V, Bass MB, and Robinson MO (1997). Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev 11, 3109-15.
12. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, and Jefferson RA (1997). Isolation of a candidate human telomerase catalytic subunit gene, which complex splicing patterns in different cell types. Hum Mol Genet 6, 2011-19.
13. Ulaner GA, Hu JF, Vu TH, Gludine LC, and Hoffman AR (1998). Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58, 4168-72.
14. Shay JW, Zou Y, Hiyama E, and Wright WE (2001). Telomerase and cancer. Hum Mol Genet 10, 677-85.
15. Shay JW (1997). Telomerase in human development and cancer. J Cell Physiol 173, 266-70.
16. Holt SE, and Shay JW (1999). Role of telomerase in cellular proliferation and cancer. J Cell Physiol 180, 10-18.
17. Wick M, Zubov D, and Hagen G (1999). Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232, 97-106.
18. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, and Cech TR (1997). Reverse transcriptase motif in the catalytic subunit of telomerase. Science 276, 561-67.
19. Yokoyama Y, Wan X, Takahashi Y, Shinohara A, and Tamaya T (2001). Alternatively spliced variant deleting exon 7 and 8 of the human telomerase reverse transcriptase gene is dominantly expressed in the uterus. Mol Hum Reprod 7, 853-57.
20. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, and Reddel RR (2000). The hTERT alpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2, 426-32.
21. Yi X, White DM, Aisner DL, Baur JA, Wright WE, and Shay JW (2000). An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2, 433-40.
22. Bustin SA (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25, 169-73.
23. Ohyashiki JH, Ohyashiki K, Toyama K, and Shay JW (1996). A non radioactive fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. Trends Genet 12, 395-96.
24. Hisatomi H, Nagao K, and Komatsu H (1997). Quantification of telomerase activity in human liver tissues by fluorescence-based TRAP analysis. Hepatol Res 7, 35-42.
25. Hiyama E, and Hiyama, K (2002). Clinical utility of telomerase in cancer. Oncogene 21, 643-49.
26. Cong YS, Wright WE, and Shay JW (2002). Human telomerase and its regulation. Microbiol Mol Biol Rev 66, 407-25.
27. Toshikuni N, Nouso K, Higashi T, Nakatsukasa H, Onishi T, Kaneyoshi T, Kobayashi Y, Kariyama K, Yamamoto K, and Tsuji T (2000). Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer 82, 833-37.
28. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, and Namiki M (1998). Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 4, 1603-608.
29. Tomoda R, Seto M, Tsumuki H, Iida K, Yamazaki T, Sonoda J, Matsumine A, and Uchida A (2002). Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors. Cancer 95, 1127-33.
30. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, and Hoffman AR (2000). Regulation of telomerase by alternative splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 85, 330-35.
31. Kanamaru T, Yamamoto M, Morita Y, Ito T, Kuroda Y, and Hisatomi H (1999). Clinical implications of telomerase activity in resected hepatocellular carcinoma. Int J Mol Med 4, 267-71.
32. Ide T, Tahara H, Nakashio R, Kitamoto M, Nakanishi T, and Kajiyama G (1996). Telomerase in hepatocellular carcinogenesis. Hum Cell 9, 283-86.
33. Yi X, Shay JW, and Wright WE (2001). Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res 29, 4818-25.
34. Gertler R, Rosenberg R, Stricker D, Werner M, Lassmann S, Ulm K, Nekarda H, and Siewert JR (2002). Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma. Cancer 95, 2103-11.
35. Kawakami Y, Kitamoto M, Nakanishi T, Yasui W, Tahara E, Nakayama J, Ishikawa F, Tahara H, Ide T, and Kajiyama G (2000). Immunohistochemical detection of human telomerase reverse transcriptase in human liver tissues. Oncogene 19, 3888-93.